Cabaletta Bio, Inc.

Report azionario NasdaqGS:CABA

Capitalizzazione di mercato: US$676.7m

Cabaletta Bio Gestione

Criteri Gestione verificati 4/4

Cabaletta Bio Il CEO è Steven Nichtberger, nominato in Jan2017, e ha un mandato di 9.33 anni. la retribuzione annua totale è $ 2.40M, composta da 27.5% di stipendio e 72.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.25% delle azioni della società, per un valore di $ 8.48M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.5 anni e 6.3 anni.

Informazioni chiave

Steven Nichtberger

Amministratore delegato

US$2.4m

Compenso totale

Percentuale dello stipendio del CEO27.46%
Mandato del CEO9.3yrs
Proprietà del CEO1.3%
Durata media del management4.5yrs
Durata media del Consiglio di amministrazione6.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Mar 24

Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 27

Cabaletta Bio: Do You Buy With The Insiders?

Summary Cabaletta Bio continues to advance its engineered cell therapy pipeline targeting autoimmune diseases, maintaining cautious optimism. Recent insider share purchases have apparently bolstered confidence in CABA’s prospects following key data releases since October. At Q3 2025, CABA reported $60.2 million in cash and $99.7 million in short-term investments, supporting ongoing development. Strengths include promising pipeline updates, while risks remain around cash runway and clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Cabaletta Bio: Finding Optimism In Dire Straits

Summary Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough cash to operate for 5–6 quarters, assuming no further expense growth or additional financing. Risks include the aggressive nature of CAR T-cell therapy for non-life-threatening diseases and competition from other cell therapy approaches. With a market cap under $150 million, CABA's stock is a potential bargain if they achieve even partial success in their pipeline. Read the full article on Seeking Alpha
Articolo di analisi • Dec 10

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 22

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Summary I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, the company’s strong cash position and lack of recent selling point to a bullish outlook. Super-positive testing results announced in mid-November would trigger significant stock gains, with the possibility of oversized returns on investment similar to 2022-23. I rate Cabaletta a Buy for a 12-month outlook, assuming a position size of less than 1% of net portfolio assets, to adequately offset greater-than-normal risk. Read the full article on Seeking Alpha
Articolo di analisi • Sep 04

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jun 28

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Summary Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries. Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing concerns, and disappointing recent data release. Cabaletta plans to continue studies on CABA-201 for various autoimmune conditions, with the next data update due before the end of the year. The next data readout feels crucial - signs of efficacy will be greeted with a surge in share price value, but poor results could drive it back into delisting territory. There is all to play for. Read the full article on Seeking Alpha
Articolo di analisi • May 22

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 31

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Summary Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic sclerosis, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
Articolo di analisi • Dec 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. By way of example, Cabaletta Bio...
Articolo di analisi • Sep 12

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
Articolo di analisi • Jun 04

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example...
Articolo di analisi • Feb 11

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
Articolo di analisi • Oct 20

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • Jul 07

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steven Nichtberger rispetto agli utili di Cabaletta Bio?
DataCompenso totaleStipendioUtili della società
Dec 31 2025US$2mUS$660k

-US$168m

Sep 30 2025n/an/a

-US$159m

Jun 30 2025n/an/a

-US$144m

Mar 31 2025n/an/a

-US$127m

Dec 31 2024US$8mUS$646k

-US$116m

Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$597k

-US$68m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$569k

-US$53m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$4mUS$542k

-US$46m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$4mUS$516k

-US$33m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$437k

-US$22m

Compensazione vs Mercato: La retribuzione totale di Steven ($USD 2.40M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.71M ).

Compensazione vs guadagni: La retribuzione di Steven è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Steven Nichtberger (64 yo)

9.3yrs
Mandato
US$2,401,555
Compensazione

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Steven Nichtberger
Co-Founder9.3yrsUS$2.40m1.25%
$ 8.5m
David Chang
Chief Medical Officer6.9yrsUS$1.24m0.0079%
$ 53.5k
Gwendolyn Binder
President of Science & Technologyno dataUS$1.26m0.028%
$ 190.3k
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno dataNessun datoNessun dato
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno dataNessun datoNessun dato
Anup Marda
Chief Financial Officer7.3yrsUS$1.53mNessun dato
Qing Yuan
Chief Technology Officer1.9yrsNessun datoNessun dato
Samik Basu
Chief Scientific Officer4.5yrsNessun datoNessun dato
Michael Gerard
General Counsel & Secretary4.7yrsNessun datoNessun dato
Heather Harte-Hall
Chief Compliance Officer4.5yrsNessun datoNessun dato
Nicolette Sherman
Chief Human Resources Officer1.5yrsNessun datoNessun dato
Arun Das
Chief Business Officer4.3yrsNessun datoNessun dato
4.5yrs
Durata media
52yo
Età media

Gestione esperta: Il team dirigenziale di CABA è considerato esperto (durata media dell'incarico 4.5 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Steven Nichtberger
Co-Founder9.3yrsUS$2.40m1.25%
$ 8.5m
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno dataNessun datoNessun dato
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno dataNessun datoNessun dato
Richard Henriques
Independent Director7.3yrsUS$152.17k0%
$ 0
Carl June
Member of Scientific Advisory Board5.8yrsNessun datoNessun dato
Mark Simon
Independent Director7.6yrsUS$140.91k0.14%
$ 937.3k
Scott Brun
Independent Director4.9yrsUS$136.84k0%
$ 0
Iain McInnes
Member of Scientific Advisory Board6.3yrsNessun datoNessun dato
Jay Siegel
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Georg Schett
Member of Scientific Advisory Board4.3yrsNessun datoNessun dato
Shawn Tomasello
Independent Director2.8yrsUS$119.17k0.020%
$ 138.1k
Catherine Bollard
Independent Director7.1yrsUS$145.57k0.0049%
$ 32.9k
6.3yrs
Durata media
64yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CABA sono considerati esperti (durata media dell'incarico 6.3 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/06 18:41
Prezzo dell'azione a fine giornata2026/05/06 00:00
Utili2025/12/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Cabaletta Bio, Inc. è coperta da 15 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Joshua SchimmerCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc
Joshua SchimmerEvercore ISI